Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
A Phase II, Four-week, Multi-center, Double-blind, Placebo-controlled Parallel Group Study to Evaluate the Safety and Efficacy of EGT0001442 in Subjects With Type 2 Diabetes Mellitus With an Ascending Dose Safety and Pharmacokinetic Evaluation Period
Sponsor: Theracos
Listed as NCT01029704, this PHASE2 trial focuses on Diabetes Mellitus Type 2 and remains completed. Sponsored by Theracos, it has been updated 8 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE2
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jul 2019 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Dec 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Theracos
For direct contact, visit the study record on ClinicalTrials.gov .